Tagged with EU

France Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new expectations of industry-public collaboration. In this interview, Marina Vasiliou reflects on how these forces are reshaping the affiliate’s mission, the…

Taiwan Vivian Kuo, General Manager at UCB, brings over two decades of pharmaceutical industry expertise across medical affairs, marketing, corporate strategy and commercial excellence. Having spent seven years at UCB, progressing from Neurology Head for Taiwan and Hong Kong to regional leadership across Southeast Asia, she now steers both affiliates through…

USA Catherine Owen Adams, CEO of Acadia Pharmaceuticals, discusses how the company’s dual commercial pillars in Parkinson’s disease psychosis and Rett syndrome are delivering much-needed impact for patients with significant unmet needs and shaping Acadia’s next phase of growth. She shares insights into the company’s expansion plans, pipeline strategy, partnership goals,…

USA Thomas Gibbs, EVP and President of Lundbeck US, details his three-decade industry journey before taking the reins of the enterprise’s most strategic market. Accounting for over half of global revenues, the US is a key contributor to Lundbeck’s patient impact and scientific delivery. Along with outlining the organisation’s Focused Innovator…

France This conversation with Bruno Dubois offers a clear, experience-driven perspective on how Alzheimer’s disease is being redefined, from diagnosis and biomarkers to prevention and early intervention. Drawing on decades at the forefront of neurology, he challenges simplified biological definitions, explains why risk must be stratified with rigour, and outlines a…

Brazil Marco Billi, International CEO of Eurofarma, shares his perspective on the company’s evolution from a Brazilian CMO (Contract Manufacturing Organisation) into one of Latin America’s most internationally active pharmaceutical groups. Billi discusses how operational discipline, long-term investment, and a strong global market mindset have underpinned Eurofarma’s sustained growth, while outlining…

Global 2025 was a year of volatility for pharma and healthcare. In particular, the speed with which the administration of Donald Trump makes (and often then changes) consequential policy decisions has left industry stakeholders in the US and globally scrambling to fall in line. There are already clear winners and losers…

France Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation. In this conversation, Dominique Bery explains how France is shaping Ipsen’s next phase of growth, from oncology leadership to deeper…

France Jazz Pharmaceuticals’ footprint in France has accelerated over recent years, driven by a sharper focus on rare and complex diseases, a sequence of strategic acquisitions and a growing role in late-stage clinical development across neuroscience and oncology. In this conversation, Franck Cousserans, General Manager France and Benelux, reflects on how…

France Pascaline Gervoson, CEO of PiLeJe, a family-owned French nutraceutical company, represents the second generation of leadership following her father’s founding vision in 1992. With 27 years within the organisation and five years as Chief Executive, she oversees a EUR 180 million enterprise specialising in dietary supplements distributed through medical prescription…

Italy Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini is setting its sights on the US.   European Union teams up with Angelini to funnel €150M to European health…

Europe Cancer is one of Europe’s most urgent health challenges. Responsible for 23 percent of all mortality on the continent, the burden is particularly acute outside the EU5, where access timelines vary dramatically. Countries in Central and Eastern Europe, for example, face some of Europe’s highest cancer mortality rates, largely due…